Logo image of NSRX

NASUS PHARMA LTD (NSRX) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:NSRX - IL0012181553 - Common Stock

7.5 USD
-0.11 (-1.38%)
Last: 12/29/2025, 8:09:45 PM
6.85 USD
-0.65 (-8.67%)
After Hours: 12/8/2025, 8:04:00 PM
Fundamental Rating

1

NSRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. NSRX has a bad profitability rating. Also its financial health evaluation is rather negative. NSRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NSRX had negative earnings in the past year.
NSRX had a negative operating cash flow in the past year.
NSRX Yearly Net Income VS EBIT VS OCF VS FCFNSRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 -1K -2K -3K -4K

1.2 Ratios

The Return On Assets of NSRX (-442.86%) is worse than 96.34% of its industry peers.
Industry RankSector Rank
ROA -442.86%
ROE N/A
ROIC N/A
ROA(3y)-605.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NSRX Yearly ROA, ROE, ROICNSRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NSRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NSRX Yearly Profit, Operating, Gross MarginsNSRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, NSRX has about the same amount of shares outstanding.
NSRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NSRX Yearly Shares OutstandingNSRX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2M 4M 6M 8M
NSRX Yearly Total Debt VS Total AssetsNSRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 200 400 600

2.2 Solvency

An Altman-Z score of 10354.55 indicates that NSRX is not in any danger for bankruptcy at the moment.
The Altman-Z score of NSRX (10354.55) is better than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 10354.55
ROIC/WACCN/A
WACCN/A
NSRX Yearly LT Debt VS Equity VS FCFNSRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 -1K -2K -3K

2.3 Liquidity

NSRX has a Current Ratio of 0.13. This is a bad value and indicates that NSRX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.13, NSRX is not doing good in the industry: 96.86% of the companies in the same industry are doing better.
NSRX has a Quick Ratio of 0.13. This is a bad value and indicates that NSRX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.13, NSRX is not doing good in the industry: 96.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.13
Quick Ratio 0.13
NSRX Yearly Current Assets VS Current LiabilitesNSRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 1K 2K 3K 4K

More info and screens

0

3. Growth

3.1 Past

NSRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -50.00%.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NSRX will show a very negative growth in Earnings Per Share. The EPS will decrease by -1488.99% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-232800%
EPS Next 2Y-5701.72%
EPS Next 3Y-1488.99%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NSRX Yearly EPS VS EstimatesNSRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Forward Price/Earnings Ratio is negative for NSRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NSRX Price Earnings VS Forward Price EarningsNSRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NSRX Per share dataNSRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.2 -0.4 -0.6

4.3 Compensation for Growth

A cheap valuation may be justified as NSRX's earnings are expected to decrease with -1488.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5701.72%
EPS Next 3Y-1488.99%

More info and screens

0

5. Dividend

5.1 Amount

NSRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

NASUS PHARMA LTD

NYSEARCA:NSRX (12/29/2025, 8:09:45 PM)

After market: 6.85 -0.65 (-8.67%)

7.5

-0.11 (-1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners42.88%
Ins Owner ChangeN/A
Market Cap67.58M
Revenue(TTM)N/A
Net Income(TTM)-3.10K
Analysts82.86
Price Target20.91 (178.8%)
Short Float %0.1%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.82%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -442.86%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-605.95%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.13
Quick Ratio 0.13
Altman-Z 10354.55
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-232800%
EPS Next 2Y-5701.72%
EPS Next 3Y-1488.99%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y4.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y38.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.1%
OCF growth 3YN/A
OCF growth 5YN/A

NASUS PHARMA LTD / NSRX FAQ

What is the ChartMill fundamental rating of NASUS PHARMA LTD (NSRX) stock?

ChartMill assigns a fundamental rating of 1 / 10 to NSRX.


What is the valuation status of NASUS PHARMA LTD (NSRX) stock?

ChartMill assigns a valuation rating of 0 / 10 to NASUS PHARMA LTD (NSRX). This can be considered as Overvalued.


Can you provide the profitability details for NASUS PHARMA LTD?

NASUS PHARMA LTD (NSRX) has a profitability rating of 0 / 10.